The Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for iDose TR (Glaukos). The new level 2 J-code, J7355, will become effective July 1, 2024. In addition, CMS’s April 2024 update of the Hospital Outpatient Prospective Payment System (OPPS) included CPT codes that are intended to be used to cover the procedural component of iDose TR implantation, 0660T and 0661T.
These codes have been assigned to ambulatory payment classification (APC) 5492 (Level 2 Intraocular Procedures), effective April 1, 2024. iDose TR is an intracameral implant that continuously releases travoprost, a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG). iDose TR is intended to improve the standard of care by addressing patient noncompliance issues and side effects associated with topical glaucoma medications.
In December 2023, the US Food and Drug Administration approved iDose TR for a single administration per eye in patients with OHT or OAG.“The receipt of a product-specific J-code for iDose TR supports our market access initiatives to enable broad access and coverage for patients suffering from open-angle glaucoma or ocular hypertension,” said Thomas Burns, Glaukos chairman and chief executive officer, in a news release.
